Amycretin research: studies, doses and safety
An experimental fullness-hormone drug studied as daily tablets and weekly injections.
Also called: Zenagamtide, NNC0487-0111, NN9487, NN 9487.
Amylin / GLP-1 co-agonists · Unimolecular GLP-1 and amylin receptor agonist; also activates calcitonin receptors.
31 registered trials: 9 completed, 22 ongoing or planned. Five human papers cover four trials and 759 participants; phase 3 has no reported results.
Key studies
- First oral trial: Oral tablets reduced weight over 12 weeks; weight was an exploratory outcome. (source)
- First injection trial: Weekly injections reduced weight, but small arms and many withdrawals limit certainty. (source)
- Diabetes: daily tablets: All three oral doses lowered HbA1c; 25 and 50 mg also reduced weight versus placebo. (source)
- Diabetes: weekly injections: Weekly injections lowered HbA1c and weight; higher doses caused more discontinuations. (source)
- Kidney function: one dose: Kidney impairment caused no clinically important exposure change after one 0.3 mg dose. (source)
- Japanese men: oral PK: Completed; efficacy and safety results are not available. (source)
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, FDA · FDA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Wegovy PI, Novo Nordisk
- Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review., Moiz A et al. · Annals of internal medicine · 2026
- Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial., Mora P et al. · Lancet (London, England) · 2026
- Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial., Mora P et al. · Lancet (London, England) · 2026
- Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis., Kamrul-Hasan ABM et al. · Endocrinology, diabetes & metabolism · 2026
- Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide., Oldenburg LIK et al. · Diabetes, obesity & metabolism · 2026
- Supplementary appendix, Mora P et al. · The Lancet · 2026
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.